Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland
Objective: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. Methods: Retrospective health care record of 61 consecutive HIV treatment-naive...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-10-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/2050312116675813 |